Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Seiko Men's Day Date Flex Band Watch SGG744
Popular Articles

Staggering Cost Of Vision Loss In Canada Underscores Urgent Need For Vision Health Plan, Says New Report
Vision loss costs Canadian society a staggering $15.8 billlion per year - significantly higher than previously estimated, according to new research study released on June 23, 2009, by CNIB and the Canadian Ophthalmological Society (COS). The study"s proponents say these costs, which are expected to increase dramatically in the years ahead, underscore the urgent need for Canada to develop a comprehensive national vision health plan.

Study Shows Risks Of Delaying ACL Reconstruction In Young Athletes
More and more children are participating and getting hurt playing sports each year. A new study presented at the American Orthopaedic Society for Sports Medicine"s (AOSSM) Annual Meeting in Keystone, Colorado, (July 9-12) details the benefits and risks of repairing a torn anterior cruciate ligament (ACL) in young athletes under the age of 14.
News of the day
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). Onalta is the Company"s lead radiotherapeutic product candidate under development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. The compound has shown the potential to selectively deliver lethal radiation to cancer cells. The proposed Phase 3 trial will confirm that administration of Onalta results in stabilization, regression or complete remission of the carcinoid tumor, and improves carcinoid-related symptoms when compared to a high-dose regimen of the current standard therapy for this disease, Sandostatin®. With EMEA"s approval of its proposed Phase 3 protocol in hand, Molecular Insight can proceed with the final clinical trial that will position Onalta for marketing authorization in the EU.
Sexual Health

Study Links Recurrence Of Abnormal Cervical Cells To Age, Treatment Type

Older women, women with a higher grade of precancerous cells and women who undergo a freezing procedure known as cryotherapy to remove abnormal cervical cells are at a higher risk than other groups that the problem cells will return or develop into cervical cancer, according to a study published in the Journal of the National Cancer Institute, Reuters reports. For the study, Joy Melnikow of the University of California-Davis and colleagues compared 37,000 women who were treated for cervical intraepithelial neoplasia -- abnormal cervical cells -- from 1986 through 2000 with 71,000 women who had no history of abnormal cervical cells.The researchers found that the risk of cervical cancer and recurrence of medium to severe degrees of CIN was highest for women who were older than age 40, who had been previously treated for severe CIN or whose abnormal cells were treated using cryotherapy. The women underwent cone biopsies a surgical procedure to remove abnormal cells were least likely to have a recurrence of CIN. According to Melnikow, recurrence was most likely to occur within the first six years after treatment. Melnikow said that women who have been treated surgically have higher risks of bleeding and preterm labor. Therefore, younger women who are planning to become pregnant might prefer cryotherapy, she said, adding that younger women"s "risk of recurrence is lower, and a recurrence can be treated again" (Steenhuysen, Reuters, 5/12). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009